Results: Swedish Orphan Biovitrum AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Swedish Orphan Biovitrum AB (publ) (STO:SOBI) shareholders are probably feeling a little disappointed, since its shares fell 5.0% to kr272 in the week after its latest quarterly results. The result was positive overall - although revenues of kr6.2b were in line with what the analysts predicted, Swedish Orphan Biovitrum surprised by delivering a statutory profit of kr1.83 per share, modestly greater than expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the current consensus from Swedish Orphan Biovitrum's eleven analysts is for revenues of kr28.5b in 2025. This would reflect a modest 5.5% increase on its revenue over the past 12 months. Per-share earnings are expected to rise 2.8% to kr13.04. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr28.1b and earnings per share (EPS) of kr13.22 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

See our latest analysis for Swedish Orphan Biovitrum

The analysts reconfirmed their price target of kr344, showing that the business is executing well and in line with expectations. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Swedish Orphan Biovitrum analyst has a price target of kr381 per share, while the most pessimistic values it at kr275. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 11% growth on an annualised basis. That is in line with its 14% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 14% per year. So although Swedish Orphan Biovitrum is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Swedish Orphan Biovitrum's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Swedish Orphan Biovitrum. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Swedish Orphan Biovitrum analysts - going out to 2027, and you can see them free on our platform here.

And what about risks? Every company has them, and we've spotted 1 warning sign for Swedish Orphan Biovitrum you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.